The limited use of interleukin-6 receptor antagonists/immune-modulating drugs, patient age, and other unexplored pathophysiological mechanisms determine the progression of vaso-occlusive crises in COVID-19 scenarios [27]. This evidence concerns the gene IL6R and COVID-19.